1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Dathyrca 1, EudrCT 2007-002713-39, HB-2007-043, Data register 2007-41-120, NCT00604318
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: rAd-p53-003, NCT00902122
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 80
Sponsor: Other
Protocol IDs: CRUK-HILO-BRD/05/83, ISRCTN56078540, EU-20665, CTA-20363/0217/001/0001, EUDRACT-2005-003687-37, NCT00415233
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Estimabl, CSET 1216, NCT00435851
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 14295, EudraCT: 2009-012007-25, NCT00984282
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 18916, NCT00279721
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061027, NCT00389441
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: Valproic Acid, NCT00525135
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: UPCC-03305, UPCC#03305, UPCC-802861, NCT00601783
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC057H, MC057H, 7627, NCT00625846
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WCI-2007-214, NCT00668811
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 802861, UPCC 03305, NCT00654238
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-08066, 08-066, 7508, NCT00729157
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-201, NCT00784303
|
|
15.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090138, 09-C-0138, NCT00923481
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-049, NCT00936858
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H-2009-0173, CO 08322, NCT01013597
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: 09-148, NCT01025453
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-11001, NCT00062348
|
|
20.
|
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: HNO-FDG-FU, NCT00180245
|
|
21.
|
Phase: No phase specified
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 100
Sponsor: NCI
Protocol IDs: JHOC-J0628, NCT00416949
|
|
22.
|
Phase: No phase specified
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GE-135-003, NCT00565721
|
|
23.
|
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: COMIRB# 07-0727, NCT00718770
|
|
24.
|
Phase: No phase specified
Type: Health services research, Treatment
Status: Approved-not yet active
Age: 18 to 45
Sponsor: Other
Protocol IDs: SMMU-2-2009-3, NCT00993837
|
